

# SPDR® S&P® Biotech ETF

## Key Features

- The SPDR® S&P® Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P® Biotechnology Select Industry™ Index (the "Index")
- Seeks to provide exposure to the Biotechnology segment of the S&P TMI, which comprises the following sub-industries: Biotechnology
- Seeks to track a modified equal weighted index which provides the potential for unconcentrated industry exposure across large, mid and small cap stocks
- Allows investors to take strategic or tactical positions at a more targeted level than traditional sector based investing

## About This Benchmark

The S&P Biotechnology Select Industry® represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted.

## Fund Information

Inception Date	01/31/2006
CUSIP	78464A870

# XBI

Fact Sheet

Equity

As of 12/31/2021

## Total Return (As of 12/31/2021)

	NAV (%)	Market Value (%)	Index (%)
<b>Cumulative</b>			
QTD	-11.02	-10.97	-10.95
YTD	-20.53	-20.44	-20.38
<b>Annualized</b>			
1 Year	-20.53	-20.44	-20.38
3 Year	15.90	15.96	15.99
5 Year	13.74	13.75	13.80
10 Year	17.97	17.98	17.78

Gross Expense Ratio (%)	0.35
Net Expense Ratio (%)	0.35
30 Day SEC Yield (%)	-0.20

Performance quoted represents past performance, which is no guarantee of future results. Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold. Current performance may be higher or lower than that quoted. All results are historical and assume the reinvestment of dividends and capital gains. Visit [ssga.com](http://ssga.com) for most recent month-end performance. Performance of an index is not illustrative of any particular investment. It is not possible to invest directly in an index. Index funds are unmanaged and do not reflect the deduction of any fees or expenses. Index returns reflect all items of income, gain and loss and the reinvestment of dividends and other income as applicable.

## Characteristics

Est. 3-5 Year EPS Growth	12.48%
Index Dividend Yield	0.09%
Price/Earnings Ratio FY1	10.17
Number of Holdings	189
Price/Book Ratio	3.64
Average Market Cap (M)	US\$8,876.77

Top 10 Holdings	Capitalization (\$Million)	Weight (%)
Arena Pharmaceuticals Inc.	5695.38	1.44
Biohaven Pharmaceutical Holding Company Ltd.	9022.88	1.07
Cytokinetics Incorporated	3823.38	0.98
Turning Point Therapeutics Inc.	2359.44	0.93
Fate Therapeutics Inc.	5579.59	0.92
BioCryst Pharmaceuticals Inc.	2490.11	0.92
Halozyme Therapeutics Inc.	5668.24	0.90
Kymera Therapeutics Inc.	3254.28	0.89
TG Therapeutics Inc.	2715.92	0.89
IVERIC bio Inc.	1742.86	0.89

Totals may not equal 100 due to rounding.

## ssga.com/etfs

### Information Classification: General

**State Street Global Advisors**  
One Iron Street, Boston MA 02210  
T: +1 866 787 2257

### Glossary

**NAV** The market value of a mutual fund's or ETFs total assets, minus liabilities, divided by the number of shares outstanding.

**Market Value** Determined by the midpoint between the bid/offer prices as of the closing time of the New York Stock Exchange (typically 4:00PM EST) on business days.

**Gross Expense Ratio** The fund's total annual operating expense ratio. It is gross of any fee waivers or expense reimbursements. It can be found in the fund's most recent prospectus.

**30 Day SEC Yield** (Also known as Standardized Yield) An annualized yield that is calculated by dividing the net investment income earned by the fund over the most recent 30-day period by the current maximum offering price.

**Est. 3-5 Year EPS Growth** Based on the underlying holdings of the fund. The actual earnings estimates for the underlying holdings are provided by FactSet, First Call, I/B/E/S Consensus, and Reuters and are used to calculate a mean 3-5 year EPS growth rate estimate.

**Index Dividend Yield** The weighted average of the underlyings' indicated annual dividend divided by price, expressed as a percentage.

**Price/Earnings Ratio FY1** The weighted harmonic average of current share price

divided by the forecasted one year earnings per share for each security in the fund. Negative and positive outliers are included in the calculation.

**Price/Book Ratio** The weighted harmonic average of closing market price divided by the most recent reported book value for each security in the fund's portfolio as calculated for the last twelve months.

### Important Risk Information

Weights are as of the date indicated, are subject to change, and should not be relied upon as current thereafter.

Investing involves risk including the risk of loss of principal.

The information provided does not constitute investment advice and it should not be relied on as such. It should not be considered a solicitation to buy or an offer to sell a security. It does not take into account any investor's particular investment objectives, strategies, tax status or investment horizon. You should consult your tax and financial advisor.

The whole or any part of this work may not be reproduced, copied or transmitted or any of its contents disclosed to third parties without SSGA's express written consent.

This communication is not intended to be an investment recommendation or investment advice and should not be relied upon as such. Funds investing in a **single sector** may be subject to more volatility than funds investing in a diverse group of sectors. Because of their narrow focus, **sector funds** tend to be more volatile than broadly diversified funds and generally result in greater price fluctuations than the overall market.

**Non-diversified fund** may invest in a relatively small number of issuers, a decline

in the market value may affect its value more than if it invested in a larger number of issuers. While the Fund is expected to operate as a diversified fund, it may become non-diversified for periods of time solely as a result of changes in the composition of its benchmark index. The Fund may not purchase securities of any issuer if, as a result, more than 5% of the Fund's total assets would be invested in that issuer's securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

**Passively managed funds** hold a range of securities that, in the aggregate, approximates the full Index in terms of key risk factors and other characteristics. This may cause the fund to experience tracking errors relative to performance of the index.

While the shares of ETFs are tradable on secondary markets, they may not readily trade in all market conditions and may trade at significant discounts in periods of **market stress**.

**ETFs** trade like stocks, are subject to investment risk, fluctuate in market value and may trade at prices above or below the ETFs net asset value. Brokerage commissions and ETF expenses will reduce returns.

**Intellectual Property Information:** Standard & Poor's®, S&P® and SPDR® are registered trademarks of Standard & Poor's Financial Services LLC (S&P); Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC (Dow Jones); and these trademarks have been licensed for use by S&P Dow Jones Indices LLC (SPDJL) and sublicensed for certain purposes by State Street Corporation. State Street Corporation's financial products are not sponsored, endorsed, sold or promoted by SPDJL, Dow

Jones, S&P, their respective affiliates and third party licensors and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability in relation thereto, including for any errors, omissions, or interruptions of any index.

The S&P Select Industry series is designed to measure the performance of narrow GICS (Global Industry Classification Standard) sub-industries. The S&P Biotech Select Industry Index is an equal-weighted index that draws constituents from the Biotechnology segment of the S&P TMI. Liquidity and market capitalization screens are applied to the index to ensure investability.

**Distributor** State Street Global Advisors Funds Distributors, LLC, member FINRA, SIPC, an indirect wholly owned subsidiary of State Street Corporation. References to State Street may include State Street Corporation and its affiliates. Certain State Street affiliates provide services and receive fees from the SPDR ETFs.

**Before investing, consider the funds' investment objectives, risks, charges and expenses. To obtain a prospectus or summary prospectus which contains this and other information, call 1-866-787-2257 or visit ssga.com. Read it carefully.**

**Not FDIC Insured  
No Bank Guarantee  
May Lose Value**

© 2022 State Street Corporation.  
All Rights Reserved.  
Tracking Number: 3414949.3.1.AM.RTL  
Expiration Date: 04/30/2022  
ETF-XBI 20220120/09:34